FreeBioList

Catalysts / NERV

Minerva Neurosciences (NERV) catalysts

Upcoming FDA decisions and readouts we track for Minerva Neurosciences, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 2 Rows last checked — 12 Sep 2026

FreeBioList tracks 2 upcoming catalysts for Minerva Neurosciences (NERV, listed on Nasdaq). Both concern Roluperidone (Negative symptoms of schizophrenia).

First on the list: the Phase 3 readout for Roluperidone (Negative symptoms of schizophrenia), guided by the company to H2 2027. By stage, the upcoming rows are 2 Phase 3 readouts.

Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: How to read a Phase 3 topline readout.

Ticker
NERV
Next catalyst
H2 2027
Type
Phase 3 readout
Listed options
Yes
Company ▾ Drug ▾ Effect / indication Next catalyst ▾ Phase / type ▾ Status ▾ Source Options
Minerva Neurosciences NERV · Nasdaq Roluperidone Negative symptoms of schizophrenia H2 2027
company guidance		 Phase 3 readout Verified 8-K exhibit 99.1 ↗ Yes
Minerva Neurosciences NERV · Nasdaq Roluperidone Negative symptoms of schizophrenia H2 2028
company guidance		 Phase 3 readout Verified 8-K exhibit 99.1 ↗ Yes

Companies working on related conditions